Neoadjuvant treatment of pancreatic ductal adenocarcinoma | springermedizin.at
Skip to main content

Home

Zeitschriften

Zeitungen

Podcast

Gesundheitspolitik

Praxis

Leben

Jobs

Fachgebiete

Allgemeinmedizin
Anästhesiologie & Intensivmedizin
Augenheilkunde
Chirurgie
Dermatologie
Gynäkologie und Geburtshilfe
HNO
Innere Medizin
Kinder & Jugendheilkunde
Neurologie & Psychiatrie
Orthopädie & Unfallchirurgie
Pflege
Urologie
Zahnmedizin
Apotheke

Subfächer Innere Medizin

Diabetologie
Gastroenterologie
Infektiologie
Kardiologie
Onkologie und Hämatologie
Pneumologie
Rheumatologie

Fortbildungen

DFP-Literaturstudium-Artikel
DFP-Webcast Fortbildungen
DFP-Podcasts
Erweiterte Suche
Login
nach oben
memo - Magazine of European Medical Oncology

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2022

10.08.2022 | short review

Neoadjuvant treatment of pancreatic ductal adenocarcinoma

verfasst von: Katharina Kosma, Sabine Thalhammer, Thomas Gruenberger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer is the subject of several ongoing randomized controlled trials (RCTs). Retrospective studies and completed RCTs favor the use of neoadjuvant therapy in pancreatic cancer. Yet, the optimal chemotherapy regimen has not been defined. The objective of this report is to provide a review of currently available study data of neoadjuvant therapy in pancreatic cancer.
Vorheriger Artikel Neoadjuvant treatment in non-small-cell lung cancer—the earlier, the better
Nächster Artikel Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer
Literatur
1.
Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308–47. CrossRef
2.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. CrossRef
3.
Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current clinical strategies of pancreatic cancer treatment and open molecular questions. Int J Mol Sci. 2019;20(18):4543. CrossRef
4.
Zaky AM, Wolfgang CL, Weiss MJ, Javed AA, Fishman EK, Zaheer A. Tumor-vessel relationships in pancreatic ductal adenocarcinoma at multidetector CT: different classification systems and their influence on treatment planning. Radiographics. 2017;37(1):93–112. CrossRef
5.
Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11. CrossRef
6.
Rhee H, Park MS. The role of imaging in current treatment strategies for pancreatic adenocarcinoma. Korean J Radiol. 2021;22(1):23. CrossRef
7.
Marion-Audibert AM, Vullierme MP, Ronot M, Mabrut JY, Sauvanet A, Zins M, et al. Routine MRI with DWI sequences to detect liver metastases in patients with potentially resectable pancreatic ductal carcinoma and normal liver CT: a prospective multicenter study. Am J Roentgenol. 2018;211(5):W217–25. CrossRef
8.
Tzeng CWD, Cao HST, Lee JE, Pisters PWT, Varadhachary GR, Wolff RA, et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014;18(1):16–25. CrossRef
9.
Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–7. CrossRef
10.
Bakens MJ, Geest LG, Putten M, Laarhoven HW, Creemers G, Besselink MG, et al. The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. Cancer Med. 2016;5(10):2825–31. CrossRef
11.
van Dam JL, Janssen QP, Besselink MG, Homs MYV, van Santvoort HC, van Tienhoven G, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140–9. CrossRef
12.
Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–58. CrossRef
13.
Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(8):1028–61. CrossRef
14.
Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A, et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020;9(4):1129. CrossRef
15.
Lee YS, Lee JC, Yang SY, Kim J, Hwang JH. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: a systematic review and meta-analysis. Sci Rep. 2019;9(1):15662. CrossRef
16.
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei ACC, Raoul JL, et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol. 2018;36(18_suppl):LBA4001. CrossRef
17.
Sugimoto M, Takahashi N, Farnell MB, Smyrk TC, Truty MJ, Nagorney DM, et al. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: a propensity matching and intention-to-treat analysis. J Surg Oncol. 2019;120(6):976–84. CrossRef
18.
Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35(5):515–22. CrossRef
19.
Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802–12. CrossRef
20.
Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7–16. CrossRef
21.
Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–22. CrossRef
22.
Ye M, Zhang Q, Chen Y, Fu Q, Li X, Bai X, et al. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. HPB. 2020;22(6):821–32. CrossRef
23.
Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73. CrossRef
24.
Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;02233:21.
25.
Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020;272(3):481–6. CrossRef
26.
Lambert A, Schwarz L, Ducreux M, Conroy T. Neoadjuvant treatment strategies in resectable pancreatic cancer. Cancers. 2021;13(18):4724. CrossRef
27.
Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial—1 (NorPACT-1))—study protocol for a national multicentre randomized controlled trial. BMC Surg. 2017;17(1):94. CrossRef
28.
Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, et al. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer—the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer. 2018;18(1):1298. CrossRef
29.
Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, et al. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy—a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer. 2018;18(1):762. CrossRef
30.
Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC‑2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer. 2021;21(1):300. for the Dutch Pancreatic Cancer Group. CrossRef
31.
Hall WA, Dawson LA, Hong TS, Palta M, Herman JM, Evans DB, et al. Value of neoadjuvant radiation therapy in the management of pancreatic adenocarcinoma. J Clin Oncol. 2021;39(34):3773–7. CrossRef
32.
Hill CS, Rosati LM, Hu C, Fu W, Sehgal S, Hacker-Prietz A, et al. Neoadjuvant stereotactic body radiotherapy after upfront chemotherapy improves pathologic outcomes compared with chemotherapy alone for patients with borderline resectable or locally advanced pancreatic adenocarcinoma without increasing perioperative toxicity. Ann Surg Oncol. 2022;29(4):2456–68. CrossRef
33.
Arcelli A, Buwenge M, Macchia G, Bertini F, Guido A, Deodato F, et al. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: a multicenter case-control study (PAULA-1). Cancer Med. 2020;9(21):7879–87. CrossRef
Metadaten
Titel
Neoadjuvant treatment of pancreatic ductal adenocarcinoma
verfasst von
Katharina Kosma
Sabine Thalhammer
Thomas Gruenberger
Publikationsdatum
10.08.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00832-7

Weitere Artikel der Ausgabe 3/2022

memo - Magazine of European Medical Oncology 3/2022 Zur Ausgabe

short review

CAR T cells in multiple myeloma: Where we stand and where we might be going

case report

Multiple myeloma with central nervous system relapse: a case report

short review

Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021

short review

Neoadjuvant treatment in non-small-cell lung cancer—the earlier, the better

review

Applicability of ESMO-MCBS and ESCAT for molecular tumor boards

editorial

Molecular profiling leading to personalized cancer treatment